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common. At the time of diagnosis, intrapulmonary metastases were 
found at seven cases (16%) 
Conclusion: Predominant radiologic ﬁnding of PA pattern adenocar-
cinoma is solitary nodule or mass with lobulation and ﬁne speculation. 
Secondary dominant CT feature is central mass or inﬁltration which are 
uncommon in adenocarcinoma. Further investigation is necessary to 
correlate pathologic ﬁndings of these two subtypes. GGO, air-broncho-
gram and consolidation is less common CT ﬁndings. Although it is not 
speciﬁc, there are several characteristic CT features to suggest subtype 
of adenocarcinoma with micropapillary pattern.
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Natural History of Small Lung Lesions with Ground-glass Opacity
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Background: In recent years, clinical use of high-resolution computed 
tomography (CT) has greatly advanced the diagnosis of small lesions of 
the peripheral lung. Such small lesion is often associated with ground-
glass opacity (GGO) in CT ﬁndings. The important issue in the man-
agement of small lung carcinoma, especially those showing pure GGO, 
is the dormant nature of the tumor. Although it has been suggested 
that the adenoma-carcinoma sequence also applies to tumorigenesis in 
adenocarcinoma of the lung, no persuasive data have been presented 
about the percentage of pure GGO lesions that are indolent over a 
long clinical course or the percentage of GGO lesions that progress to 
become solid lesions. The timeframe for small GGO lesions to progress 
to solid tumors is also unclear. To avoid an overdiagnosis bias and un-
necessary surgery, it is important to elucidate the natural history of the 
small lung lesions showing GGO features.
Methods: We investigated clinicopathological ﬁndings of 18 patients 
with small peripheral lung lesions showing pure GGOs or part-solid 
GGOs deﬁned with CT and retained for more than six months. After 
long-term observation, three of 18 patients underwent pulmonary resec-
tion, and 15 are currently being followed. 
Results: The patients comprised six men and 12 women, ranging in 
age from 37 to 80 years. The median follow-up period was 25 months, 
ranging from 6 to 72 months. The size of lesion at the time of ﬁrst 
presentation was 5 to 22 mm in largest diameter. There were 12 patients 
with solitary lesion and six had multiple lesions raging in number 2 to 
20. Of the 18 patients, 10 showed pure GGO on CT and 8 with part-
solid GGO type. During follow-up, the size of lesion showed no change 
(±1mm) in 13 (72%) patients, increased slightly (up to 5mm) in three 
(17%), and increased by more than 5mm and showed new lesions in 
two (11%). Of the 10 patients with pure GGO, 9 showed no change in 
size of the lesion. Three patients underwent limited pulmonary resec-
tion (segmentectomy in two patients and wedge resection in one) with 
negative surgical margin. Of them, two patients had adenocarcinoma 
and one bronchioloalveolar carcinoma. There was no clear tendency 
between the degree of size change and histology. All patients are alive.
Conclusions: Previous reports have often suggested that the manage-
ment of GGO lesions should differ from the management of small, 
peripheral, noncalciﬁed solitary nodules showing soft-tissue density. 
Our data suggest that some small lung lesions, especially showing pure 
GGO, will never progress to clinical disease and might be overdiag-
nosed.
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Comparison of WHO and RECIST criteria for assessment of 
response in patients with lung cancer- A pilot study
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Objective tumor response is a common endpoint in daily practice as 
well as in clinical trials to evaluate the efﬁcacy of anti-cancer agents. 
To maintain uniformity we are following the consensus statements 
for long times. The general sense suggests that any tumor response is 
always three dimensional. However by the application of the math-
ematical models we gradually reduced it to two dimensions (WHO). 
However progress in imaging technology mandated new methodology 
to evaluate response to treatment. One among such is the Response 
Evaluation Criteria in Solid Tumors Group (RECIST) guidelines using 
unidimensional measurement. Theoretically, the simple sum of the 
maximum diameters of individual tumors is not accepted by many on-
cologists as a representative of cell kill than is the sum of the bidimen-
sional products and they prefer 3D. many previous trails have resolved 
this issue and presently the RECIST is considered as gold standard. 
However the practice of radiologists is not uniform and therefore we 
thought of comparing WHO and RECIST criteria 
Methods: A total of 48 previously untreated patients with locally 
advanced or metastatic NSCLC during 2004 to 2006 with an ECOG 
performance status (PS) scale of ? 2 were included. Patients received 
either a combination of Gemcitabine and Cisplatin; Gemcitabine and 
Carboplatin or cisplatin with etoposide. Gemcitabine was given at a 
dosage of 1250mg/m2 on days 1and 8 of a 3 weekly cycle, while Cis-
platin was given at 75-100mg/m2 and Carboplatin at an AUC of 6 once 
every three weeks. Etoposide was given as 100mg/m2 infusion per day 
over 3 days. 
The treatment arms were based on the socioeconomic status of the 
patient.The responses were assessed with either a chest X ray or a CT 
scan again based on the economic status and the method was main-
tained constant all through the study. Response was assessed as per the 
RECIST criteria as well as WHO criteria. Assessment was done at end 
of every 2nd cycle and conﬁrmed after 4 weeks of initial response. The 
tests repeated if clinically indicated.Our study shows the wide discrep-
ancy between the WHO and the RECIST assessment systems and thus 
the need to evaluate on similar scales.
The ideal system seems to be the one that would simply look at the 
volume in a 3 dimensional way.
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Is natural history of non-small cell lung cancer in accordance to 
TNM staging system?
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The International Staging System,is currently based on prognostic 
data, mainly issued from surgical series. It is generally considered that 
locally advanced non-small cell lung cancers have to be treated by 
multimodal approaches, at least including induction or adjuvant chemo-
therapy, because their propensity to distant metastatic spreading. Pre-
sumably those patients without N2 or N3 lymph node involvement will 
be referred to surgery, because disease progression is more expected at 
the locoregional level. Authors retrospectively reviewed 392 patients 
